Vertex Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $580.63, Implies 5% Upside

What happened

According to estimates from 27 analysts, Vertex Pharmaceuticals' average price target rose from $575.96 to $580.63, with forecasts ranging from $350 to $667 per share. Based on the Nov. 2 closing price, this implies about 5% potential upside.

Confirmed

Global impact / market context

A higher average target means analysts on balance expect the shares to be worth more than before. That can support investor confidence and demand for the stock. But the wide $350 to $667 range shows analysts disagree a lot about the company's future value.

Analyst inference

The consensus rating stays at Buy across 35 covering analysts, split into 27 Buys, 6 Holds and 2 Sells. That suggests most analysts remain positive on Vertex, while a small group is more cautious. The modest 5% upside implies shares already trade close to the average target.

Analyst inference

What to watch

1. The analyst count matters: 27 analysts set the price targets, while 35 analysts set ratings. A growing or shrinking group of forecasters can change both the average target and the consensus rating over time. Confirmed
2. Watch whether the average target keeps rising toward the $667 high forecast or slips toward the $350 low forecast. Movement toward either end would signal that analyst views are becoming more united in one direction. Proposed
3. Track the gap between the stock price and the $580.63 average target. If the shares rise and close that gap, the implied upside shrinks, which may reduce the stock's appeal to investors seeking bargains. Analyst inference

Evidence

• Original source link unavailable